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 ABSTRACT
Severe chronic kidney disease may lead to disturbances, such as hyperphosphatemia, increased secretion 
of fibroblast growth factor -23 (FGF -23) and vitamin D deficiency. These may increase plasmatic levels of 
parathyroid hormone, and decrease plasmatic levels of calcium. Altogether, these may contribute to the 
development of secondary hyperparathyroidism, and to abnormalities in mineral metabolism. Kidney trans-
plantation is the best option to improve longevity and quality of life in end -stage chronic kidney disease 
patients. Vitamin D deficiency has been associated with cardiovascular disease, which is the leading cause 
of death in chronic kidney disease. Therefore, diagnosing this deficiency may be pivotal for minimizing 
mortality in chronic kidney disease, because pharmacological treatments for this deficiency may be pre-
scribed. Calcitriol is indicated for the treatment of vitamin D deficiency, both in chronic kidney disease and 
in kidney transplanted patients. However, calcitriol may increase the plasmatic levels of calcium and phos-
phorous, which can lead to vascular calcifications, that have been associated with cardiovascular mortality. 
Selective vitamin D receptor activators are indicated for the treatment of vitamin D deficiency in chronic 
kidney disease. These have the advantage of being associated with lower increases of plasmatic levels of 
calcium and phosphorous. These drugs also seem to have additional effects that may minimise patient 
morbidity and mortality, especially due to potentially reducing cardiovascular events. Unfortunately, there 
are few studies about the use of these drugs in kidney transplanted patients. Here we present a review 
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 INTRODUCTION
Disturbances in bone and mineral metabolism may 
be observed since early stages of chronic kidney 
disease (CKD). For example, mild CKD (or stage 2 
CKD), is characterised by an estimated glomerular 
filtration rate (GFR) between 60 and 90 ml/min/1.73 
m2, as well as by disturbances in bone and mineral 
metabolism, such as increased levels of fibroblast 
growth factor - 23 (FGF -23), and decreased levels of 
calcidiol and calcitriol. Usually, at these stages of CKD, 
serum phosphate levels are either normal or reduced, 
due to the effects of the phosphaturic hormones 
(FGF -23 and parathyroid hormone [PTH]) on the kid-
ney tissue that still responds to these, and also due 
to the decrease in intestinal phosphate absorption 
(consequence of the vitamin D deficiency)
More severe CKD, such as stage 5 CKD, is char-
acterized by a GFR < 15 mL/min/1.73 m2 and, if 
untreated, by severe disturbances in bone and 
mineral metabolism, such as hyperphosphatemia, 
about the physiology of vitamin D, the consequences of its deficiency in chronic kidney disease and in 
kidney transplanted patients, and about the diagnosis and treatment of this deficiency. Finally, we discuss 
the new line of research about the efficacy and safety of selective vitamin D receptor activators in kidney 
transplanted patients.
Key -Words: Calcitriol; cholecalciferol; CRF -chronic renal failure; paricalcitol; renal Insufficiency, chronic; 
review; vitamin D.
 RESUMO
A doença renal crónica pode conduzir a distúrbios metabólicos como hiperfosfatemia, aumento da secre-
ção do “fibroblast growth factor - 23”, e deficiência de vitamina D, que por sua vez, podem conduzir a um 
aumento dos níveis plasmáticos da paratormona, e a uma diminuição dos níveis plasmáticos de cálcio. 
Consequentemente, a doença renal crónica pode contribuir para o desenvolvimento de hiperparatiroidismo 
secundário, e de anomalias no metabolismo mineral ósseo. A transplantação renal é a opção que propor-
ciona a maior longevidade e qualidade de vida, a doentes com doença renal crónica terminal. A deficiência 
de vitamina D tem sido associada a doença cardiovascular, que é a causa principal de mortalidade nos 
transplantados renais. Logo, o diagnóstico desta deficiência poderá ser crucial para tentar minimizar esta 
mortalidade, uma vez que esta deficiência de vitamina D pode ser corrigida terapeuticamente. O calcitriol 
tem como indicação terapêutica o tratamento da deficiência de vitamina D, tanto em doentes com doença 
renal crónica, como em doentes transplantados renais. No entanto, este fármaco pode aumentar os níveis 
plasmáticos de cálcio e de fósforo, conduzindo a potenciais calcificações vasculares, que têm sido asso-
ciadas a mortalidade cardiovascular. Os ativadores seletivos dos recetores da vitamina D têm como indicação 
terapêutica o tratamento da deficiência de vitamina D na doença renal crónica. A vantagem destes fármacos 
é que têm sido associados a aumentos inferiores dos níveis plasmáticos de cálcio e fósforo. Estes fármacos 
têm ainda efeitos adicionais que podem minimizar a morbilidade e a mortalidade, principalmente devido 
ao seu potencial para reduzir eventos cardiovasculares. Neste artigo apresentamos uma revisão de literatura 
sobre a fisiologia da vitamina D, sobre as consequências da sua deficiência na doença renal crónica e em 
doentes transplantados renais, e sobre o diagnóstico e tratamento desta deficiência. Finalmente, discutimos 
os resultados de estudos recentes, sobre a segurança e eficácia dos ativadores seletivos dos recetores da 
vitamina D em doentes transplantados renais.
Palavras -Chave: Calcitriol; colecalciferol; insuficiência renal, crónica; paricalcitol; revisão; vitaminaD.
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increase in FGF -23, and active vitamin D deficiency, 
due to a decreased activity of the 1α -hydroxylase 
(an enzyme mainly present on the tubular cells of 
the kidney, that hydroxylates 25 -OH -vitamin D)1. This 
leads to the rise of the plasmatic levels of PTH and 
eventually to hypocalcaemia. Altogether, these con-
tribute to the development of secondary hyperpara-
thyroidism (SHPT) and to abnormalities in mineral 
metabolism.
Kidney transplantation is the treatment option 
that offers the best longevity and quality of life for 
end -stage CKD patients. However, although success-
ful kidney transplantation may improve GFR, kidney 
transplanted patients may still have CKD, which may 
lead to severe mineral bone metabolic disease. 
Furthermore, despite a better 1α -hydroxylase activity, 
kidney transplanted patients may still have vitamin 
D deficiency for several reasons, such as: inade-
quately high FGF -23 serum levels, regular use of 
corticosteroids (part of the normal post -transplant 
immunosuppressive therapy), low exposure to sun 
light (normally recommended to prevent cutaneous 
tumours), diet restrictions, and mild to moderately 
decreased kidney function always present after kid-
ney transplant.
Vitamin D deficiency has been associated with 
cardiovascular disease (CVD), which is the leading 
cause of death in CKD2. There is no clear evidence 
from randomised controlled trials that vitamin D 
supplementation may be associated with a reduction 
of mortality in CKD patients. However, according to 
a meta -analysis by Duranton et al.3 that included 14 
observational studies (observing altogether more than 
35,155 deaths, in a total population of 194,932 
patients with CKD or undergoing dialysis), supplemen-
tation with vitamin D derivatives is significantly associ-
ated with a 27% relative risk reduction of all -cause 
mortality (relative risk 0.73, 95% CI 0.65–0.82) and 
with 37% relative reduction of cardiovascular mortality 
risk (relative risk 0.63, 95% CI 0.44–0.92). Therefore, 
diagnosing vitamin D deficiency in CKD may be pivotal 
for minimizing mortality of CKD patients, because 
appropriate pharmacological treatments may be pre-
scribed for this deficiency.
Calcitriol has been prescribed to treat vitamin D 
deficiency both in CKD and in kidney transplanted 
patients4. Although calcitriol may treat this deficiency, 
undesirably it also may increase the plasmatic levels 
of calcium and phosphorous, which can lead to vas-
cular calcifications that have been associated with 
mortality5 -7.
Alternatively, selective vitamin D receptor activa-
tors (VDRAs) may also be used to treat vitamin D 
deficiency in CKD, with the advantage of being 
associated with a lower incidence of hypercalcaemia 
and hyperphosphatemia8 -10. Furthermore, these 
drugs also seem to have non -inflammatory (including 
immunomodulatory) and anti -inflammatory effects, 
which may minimise patient morbidity and mortality, 
especially due to potentially reducing cardiovascular 
events11 -13.
Given the benefits of paricalcitol in CKD (the only 
selective VDRA drug currently licensed in Europe and 
USA), it is possible to hypothesise that this drug 
may also benefit kidney transplanted patients. Unfor-
tunately, there are few studies investigating this.
In this review we present an overview about the 
physiology of vitamin D, the consequences of its 
deficiency in CKD, especially after kidney transplanta-
tion. Furthermore, we discuss the state of the art 
about the treatment of vitamin D deficiency in CKD, 
including the non -inflammatory (including immuno-
modulatory) and anti -inflammatory benefits of selec-
tive VDRA therapy. Finally, we discuss the current 
line of research about the efficacy and safety of 
selective VDRAs in kidney transplanted patients.
 THE PHYSIOLOGY OF VITAMIN D
Vitamin D is a steroid -derived hormone whose 
activation requires several enzymatic steps. Briefly, 
7 -dehydrocholesterol is photo -activated in the skin 
into cholecalciferol, which is then converted in the 
liver into calcidiol (25[OH]D), which is finally converted 
in the kidney (by the 1α -hydroxylase) into calcitriol 
(1,25[OH]2D3) that is the most active form of vitamin 
D. Then calcitriol binds to nuclear vitamin D receptors 
(VDRs), regulating the expression of more than 200 
genes, such as those encoding the FGF -23 and its 
co -receptor klotho. These play a major role in the 
regulation of plasmatic calcium and phosphorous
Vitamin D deficiency has been associated with 
opportunistic infections after kidney transplanta tion14, 
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and cancer15, and it is not yet clear whether vitamin 
D supplementation may prevent these16, 17. Further-
more, as presented below, this deficiency may also 
lead to SHPT, CVD, and to poor outcomes after kidney 
transplantation.
  VITAMIN D DEFICIENCY AND 
SECONDARY HYPERPARATHYROIDISM
Secondary hyperparathyroidism is a common 
metabolic disorder that may occur due to vitamin 
D deficiency, both in CKD18 and in post -kidney 
transplantation patients19. This disorder is char-
acterized by an increased synthesis of PTH by 
the parathyroid gland, contributing to bone 
mass loss20 and hypercalcaemia21. Therefore, the 
reduction of the plasmatic levels of PTH toward 
normal levels is a strategy for preventing or treat-
ing SHPT. As it will be presented in detail later 
in this review, this can be done using drug 
classes such calcimimetics, non -selective VDRAs, 
and selective VDRAs. Treating SHPT is important 
because this disease has been associated with 
CVD, due to ventricular hypertrophy and coronary 
heart disease22.
  VITAMIN D DEFICIENCY AND 
CARDIOVASCULAR DISEASE
Vitamin D deficiency has been associated with 
CVD morbidity and mortality. A recent cohort 
study23 investigated the association between pre-
-operative plasmatic levels of calcidiol (a precursor 
of vitamin D) and major cardiac and cerebral vas-
cular events in a sample of 4,418 cardiac surgical 
patients. For 38.0% of patients these levels were 
deficient (i.e., < 30 nmol/L), for 32.3% insufficient 
(i.e., between 30 and 49.9 nmol/L), and for 3.1% 
high (i.e., > 100 nmol/L). The odds ratio for major 
cardiac and cerebrovascular events was 2.23 (95% 
CI, 1.31 -3.79) for deficient levels, 1.73 (95% CI 1.01-
-2.96) for insufficient levels, and 2.34 (95% CI, 
1.12 -4.89) for high levels, when compared to cal-
cidiol levels between 75 -100 nmol/L. Therefore, it 
was concluded that vitamin D deficiency is prevalent 
in pre -operative cardiac surgical patients, and that 
it is an independent risk factor for major cardiac 
and cerebral vascular events. Further research is 
still needed to investigate whether native vitamin 
D supplementation may reduce the risk of CVD in 
CKD patients24.
  THE ROLE OF VITAMIN D 
DEFICIENCY IN THE OUTCOME 
OF KIDNEY TRANSPLANTATION
Vitamin D deficiency has been associated with 
a poor outcome of renal transplantation, but it is 
unclear whether this may be improved by correct-
ing this deficiency. For example, a retrospective 
study25 suggested that vitamin D supplementa-
tion, between 3 and 12 months post -transplantation, 
did not confer structural and functional nephro-
protection in a sample of 64 patients. However, 
a recent study26 suggested that vitamin D supple-
mentation, within the first 90 days post-
-transplantation, was associated with fewer cases 
of acute cellular rejection. Further research is still 
needed to investigate whether vitamin D supple-
mentation may improve the outcome of kidney 
transplantation.
For all the above, the diagnosis of vitamin D 
deficiency in CKD, and in post -kidney transplanta-
tion, may be pivotal for deciding on the appropriate-
ness of prescribing a treatment for it. This may 
potentially prevent not only SHPT and CVD, but also 
poor kidney transplantation outcomes, reducing 
morbidity and mortality of CKD patients.
  DIAGNOSIS OF VITAMIN D 
DEFICIENCY
Vitamin D deficiency is diagnosed by dosing defi-
cient plasmatic levels of calcidiol. However, there is 
no consensus regarding its normal and pathological 
plasmatic levels. Generally, plasmatic levels of cal-
cidiol between 30 and 150 ng/ml (75 -375 nmol/l) are 
indicative of normal vitamin D levels, above 150 ng/
ml (375 nmol/l) are indicative of excessive vitamin 
D levels, between 20 and 30 ng/ml (50 -75 nmol/l) 
are indicative of deficient vitamin D levels, and 
below 20 ng/ml (50 nmol/l) are indicative of severely 
deficient vitamin D levels2, 27.
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  TREATMENT OF VITAMIN D 
DEFICIENCY IN SECONDARY 
HYPERPARATHYROIDISM
Secondary hyperparathyroidism may be treated 
with calcimimetic drugs (e.g., cinacalcet), and/or with 
vitamin D receptor activators (VDRAs), which may be 
non -selective (e.g., alfacalcidiol, calcitriol) or selec-
tive (e.g., paricalcitol)10, 28. Cinacalcet can induce 
hypocalcaemia and, therefore, it requires frequent 
monitorization of the plasmatic levels of calcium. 
Calcitriol has been used to treat SHPT in CKD 
patients, because it binds to VDRs in the parathyroid 
glands reducing PTH production29. It also acts in the 
intestines increasing calcium absorption, and in the 
bones balancing their reabsorption and formation. 
Unfortunately, this treatment has important side 
effects such as hypercalcaemia and hyperphospha-
temia, which may increase the risk of extraosseous 
calcifications that have been associated with 
increased cardiovascular mortality6.
Unlike with non -selective VDRAs, selective VDRAs 
are more specific to VDRs located in the parathyroid, 
rather than those located in the intestines and bone. 
Therefore, the action of selective VDRAs results in 
lower increases of the plasmatic levels of calcium 
and phosphate8, 9. Paricalcitol is the only commer-
cially available selective VDRA in Europe and USA, 
and it is licensed for the prevention and treatment 
of SHPT in CKD patients (stages 3, 4, and 5), both 
in pre -dialysis and during dialysis.
Paricalcitol reduces PTH levels, with fewer cases 
of hypercalcemia and hyperphosphatemia, and 
prevents deleterious bone reabsorption. According 
to an early double blind randomised controlled 
trial9, paricalcitol decreased PTH plasmatic levels 
in CKD patients with SHPT, by approximately 60% 
over 12 weeks of study, and it led neither to hyper-
calcaemia, nor to significant increases in plasmatic 
phosphate levels. Furthermore, a recent prospective 
observational study8 investigated the safety and 
efficacy of intravenous paricalcitol in the treatment 
of SHPT in 1,313 dialysed patients. After 6 months 
of treatment, a PTH reduction of ≥ 30% was 
observed in 63.0% of the patients, and a PTH 
reduction of ≥ 60 % was observed in 35.9% of 
patients. Furthermore, calcium and phosphorous 
levels remained stable over time in the majority of 
patients, and alkaline phosphatase (i.e., a bone 
turn -over marker) plasmatic levels improved signifi-
cantly (p < 0.0001) from baseline (median = 98U/L) 
to study end (median = 83 U/L).
Further research is still needed to compare all-
-cause mortality, CVD morbidity, and CVD mortality, 
for SHPT patients treated with paricalcitol versus 
cinacalcet24. In a recent RCT30, the use of paricalcitol 
was associated with beneficial effects on bone turn-
over markers (alkaline phosphatase and bone spe-
cific alkaline phosphatase) when compared to 
cinacalcet. However, levels of FGF -23 were increased 
with paricalcitol, and this could suggest that pari-
calcitol was associated with a higher risk of death 
than cinacalcet. This result may be explained by the 
different mechanisms of action of these drugs. Cina-
calcet reduces PTH plasmatic levels by antagonizing 
calcium -sensing receptors, whereas paricalcitol does 
this by activating VDRs, which may also promote the 
production of FGF -23. The authors of this study sug-
gested that it is necessary to further investigate the 
association between FGF -23 and death, because 
paricalcitol has been consistently associated with 
decreased mortality in numerous studies31 -37.
Observational studies suggest that the risk of 
death (from all causes) in CKD patients is signifi-
cantly reduced with paricalcitol versus calcitriol, or 
no treatment. For example, a cohort study37 inves-
tigated survival in 67,399 patients on haemodialysis, 
taking either paricalcitol (n = 29,021) or calcitriol (n 
= 38,378). It suggested that patients taking parical-
citol had 16% (95% CI; 10 -21) superior 3 -year survival 
rate than those taking calcitriol. Increased survival 
rates were also identified for patients taking pari-
calcitol versus no treatment31 - 35, but survival rates 
for paricalcitol (15.3 [95% CI; 13.6 -16.9] deaths/100 
patient -years) versus doxercalciferol (15.4 [95% CI; 
13.6 -17.1] deaths/100 patient -years) were not found 
to be significantly different33.
Studies have also reported that paricalcitol is 
associated with lower CVD mortality, when compared 
to calcitriol. Indeed, it was reported that the CVD 
death rates for patients taking paricalcitol were 0.106 
per person -year, whereas for those taking calcitriol 
were 0.128 per person -year37. Similarly, lower death 
rates due to CVD were also identified for treatment 
with alfacalcidiol when compared to no treatment36. 
These results are encouraging, because it is known 
that CVD is a major cause of death in CKD patients.
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Curiously, studies report that CKD patients taking 
paricalcitol have lower mortality rates, independently 
of the plasmatic levels of calcium, phosphorous, or 
PTH at the end of study35, 37. This suggests that the 
benefits of paricalcitol may not be limited to its 
effects on mineral and PTH metabolism. In fact, as 
presented below, several studies proposed different 
potential non -inflammatory (including immunomodu-
latory) and anti -inflammatory effects for paricalcitol 
(or selective VDRAs) that may explain its improved 
survival rates in CKD patients5.
  NON -INFLAMMATORY AND 
ANTI -INFLAMMATORY EFFECTS 
OF SELECTIVE VITAMIN D 
RECEPTOR ACTIVATORS
Four non -inflammatory effects have been identi-
fied for selective VDRAs. Firstly, selective VDRAs 
regulate the plasmatic levels of PTH, with a low 
incidence of hypercalcaemia and hyperphosphate-
mia38. This is important because increased levels of 
phosphate and calcium may contribute to vascular 
calcifications6. Secondly, studies in animals showed 
that treatment with paricalcitol may also prevent 
these vascular calcifications, by interactions with 
vascular smooth muscle cells6. Thirdly, studies in 
animals showed that paricalcitol improves left ven-
tricular function13. Finally, studies in animals also 
showed that paricalcitol treatment suppresses the 
renin -angiotensin system (RAS), which may poten-
tially decrease the risk of hypertension, myocardial 
infarction and stroke11. However, further research is 
still needed to further investigate the last 3 effects 
in humans.
Recently, in the PENNY study5, a positive role of 
paricalcitol in conditioning endothelium -dependent 
vasodilatation was described. In fact, a significant 
endothelium -dependent vasodilatation and change 
in low -mediated dilation in paricalcitol treated 
patients was observed. Furthermore, the post -hoc 
analysis of PRIMO study7 showed that CKD patients 
randomized to the paricalcitol arm developed less 
atrial volume.
Chronic kidney disease is characterized by 
chronic inflammation39, which is strongly correlated 
with increased morbidity and mortality40. Such as 
calcitriol, selective VDRAs also have anti-
-inflammatory effects. In fact, an in vitro study12 
demonstrated that calcitriol and paricalcitol have 
immunomodulatory effects, by inhibiting the matu-
ration of dendritic cells, and consequently decreas-
ing the production of bioactive IL -2. Furthermore, 
in a randomised placebo -controlled trial41 with CKD 
patients (stages 2 and 3), it was observed that 
treatment with paricalcitol for a month reduced 
inflammation status, by decreasing reactive C pro-
tein levels. As similar results were obtained in other 
studies42 -44, it is possible to raise the hypothesis 
that paricalcitol treatment may reduce inflammation 
status, decreasing the risk of atherosclerosis in CKD 
patients.
Kidney transplantation is the best option for 
decreasing mortality in end -stage CKD patients. 
Despite this, nearly all renal transplanted patients 
have a decreased GFR (lower than 60 mL/min per 
1.73 m2), when compared with normal native kidney 
function. Furthermore, vitamin D deficiency may 
remain in renal transplanted patients due to several 
reasons (e.g., corticosteroid therapy, decreased 
exposure to sun light). As it will be presented 
below, there are few studies investigating whether 
the benefits of paricalcitol identified for CKD 
patients can also be identified in kidney trans-
planted patients.
  EFFICACY AND SAFETY OF 
SELECTIVE VITAMIN D RECEPTOR 
ACTIVATORS IN KIDNEY 
TRANSPLANTED PATIENTS
To our knowledge, there are only 6 published 
studies investigating the efficacy and safety of 
paricalcitol in the treatment of SHPT in kidney 
transplanted patients (see Table I). Four45 -48 of 
these were reported in original articles, and 2 in 
conference abstracts49, 50. Among these studies, 4 
were interventional (i.e., 3 randomised, open -label, 
parallel two -arm studies46, 48, 50, and 1 randomised, 
open -label, crossover, two -arm study45), 2 were 
observational (1 prospective cohort study47, and 1 
retrospective cohort study49), 4 included a control 
group45, 46, 48, 50 and 2 did not47, 49. The number 
of patients included varied between 1248 and 
10050. The prescribed doses of oral paricalcitol were: 
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Table I
Studies investigating the efficacy and safety of paricalcitol in the treatment of secondary hyperparathyroidism in kidney transplanted patients
Authors Patients, study design, and follow -up Interventions PTH levels
Trillini M. et al. 
201445
Patients (N = 43):
> 18 -year -old kidney transplanted patients with secondary 
hyperparathyroidisma
Study design:
Randomized, open -label, crossover two -arm study (6 
months treatment with oral paricalcitol, followed by 6 




1 μg/day of paricalcitol. If this dose was tolerated (cal-
cium ≤ 10.2 and phosphate ≤ 5.1 mg/dL) for 3 months, it 
was increased to 2μg/day
Control:
Treatment without paricalcitol
After 3 months of paricalcitol: Significant reduction 
(p < 0.001) for treatment with paricalcitol 1μg/day 
(median = 77.90 [60.50 -106.50] pg/mL) vs. control 
at the same time point (median = 116.45 [84.50-
-158.10] pg/mL)
After 6 months of paricalcitol:
Significant reduction (p < 0.001) for treatment with 
paricalcitol 2μg/day (median = 63.25 [52.00 -79.70] 
pg/mL) vs. control at the same time point (median 
= 128.00 [94.00 -166.40] pg/mL)
Amer H. et al. 
201348
Patients (N = 100):
> 18 year -old patients receiving first or second kidney 
transplant, and eligible for the corticosteroid avoidance 
immunosuppression protocol offered at Mayo Clinicb
Study design:
Randomized, open -label, parallel, two -arm study
Follow -up:
1 year
Treatment (n = 51):
Calcium carbonate supplement (500 mg of elemental 
calcium) twice a day, in combination with:
–  Paricalcitol 1 μg/day orally (between days 3 to 15 post-
-transplant)
–  Paricalcitol 2 μg/day orally (from day 15 post -transplant 
onwards), only if no hypercalcaemia
Control (n = 49):
Calcium carbonate supplement (500 mg of elemental 
calcium) twice a day
Transplant day (day 0):
No significant (p ≥ 0.05) differences between treat-
ment (median = 198 pg/mL) and control (median = 
236 pg/mL)
21 days post -transplant:
Significantly (p = 0.005) lower for treatment (median 
= 50 pg/mL) vs. control (median = 69 pg/mL)
90 days post -transplant:
Significantly (p < 0.0001) lower for treatment (medi-
an = 42 pg/mL) vs. control (median = 70 pg/mL)
365 days post -transplant:
Significantly (p = 0.0004) lower for treatment (medi-
an = 42 pg/mL) vs. control (median = 85 pg/mL)
Gonzalez E. 
et al. 201347
Patients (N = 58):





Treatment (N = 58):
Oral paricalcitol (1 μg on alternate days)
Reduction of baseline PTH ≥ 30%:
55% of patients (n = 32) at month 3; 65% of patients 
(n = 38) at month 6; 69% of patients (n = 40) at 
month 9; 72% of patients (n = 42) at month 12; 75% 
of patients (n = 44) at month 18; 75% of patients (n 
= 44) at month 24
Perez V. et al. 
201346
Patients (N = 52):
Stable post -kidney transplantation patientsd
Study design:
Randomized, parallel, two -arm study
Follow -up:
12 months
Treatment (n = 31):
Oral paricalcitol 1 μg/day orally
Control (n = 21):
No paricalcitol
Treatment:
Significant reduction from baseline (median = 110.00 
[74.80 -140.30]pg/mL) to month 3 (median = 74.25 
[47.35 -93.88]pg/mL; p < 0.001), and to month 12 
(median = 59.70 [40.30 -90.60]pg/mL; p < 0.001)
Control:
Non -significant change (p ≥ 0.05) from baseline 
(median = 92.80 [71.13 -118.65] pg/mL) to month 3 
(median = 89.20 [70.13 -120.85] pg/mL), and to 
month 12 (median = 79.15 [63.78 -134.05] pg/mL)
Oliden C. et al. 
201250
Patients (N = 12):
Post -kidney transplantation patientse
Study design:
Randomized, open -label, parallel, two -arm study
Follow -up:
24 weeks
Treatment (N = 6)
Oral paricalcitol (no dose reported)
Control (N = 6)
Oral calcitriol 0.25 mg/day
Reduction of baseline PTH ≥ 30%:
6/6 patients in the treatment group vs. 3/6 patients in 
the control group (OR: 2; 95% CI 1.1 to 4.4; p = 0.046)
Valga E. F. et al. 
201249
Patients (N = 66):





Treatment (N = 66)
Paricalcitol 1 μg 3 times a week
Significant (p = 0.006) decrease from baseline 
(median = 175 [120 -175]pg/mL) to month 3 (median 
= 157 [98 -227]pg/mL)
Note: aInclusion criteria: serum intact parathyroid hormone levels >80 pg/mL (after a natural vitamin D or analogues washout period of at least 1 -month), serum calcium ≤ 10.2 mg/dL, serum creatinine < 2 mg/dL, maintenance 
immunosuppressive therapy with calcineurin inhibitors and mycophenolate mofetil or azathioprine, no ongoing therapy with vitamin D analogues, and no evidence of active hepatitis C or B virus; or HIV infection or drug or 
alcohol abuse; Exclusion criteria: Patients with previous history of hypersensitivity, allergy, or intolerance to paricalcitol, changes in serum creatinine > 30% or acute rejection episodes over the last 6 months, or chronic clinical 
conditions expected to affect completion of the study or jeopardize data interpretation as well as pregnant, lactating, or fertile women without adequate contraception; bInclusion criteria: ≥ 18 -year -old patients, receiving their 
first or second compatible kidney transplant and eligible for the corticosteroid avoidance immunosuppression. Exclusion criteria: prior hypercalcaemia, total 25 -hydroxyvitamin D <10 ng/mL, recipients of multiple organs, or receiv-
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Benefits of selective vitamin D receptor activators in kidney transplanted patients
Plasmatic levels of calcium 
and phosphorous
Glomerular filtration rate, creatinine 
clearance or serum creatinine Proteinuria Adverse events
Calcium (after 3 months of paricalcitol):
No significant differences (p ≥ 0.05) between treat-
ment with paricalcitol 1μg/day (mean = 9.59 [0.44] 
mg/dL)and control (mean = 9.53 [0.50] mg/dL)
Calcium (after 6 months of paricalcitol):
No significant differences (p > 0.05) between 
treatment with paricalcitol 2μg/day (mean = 
9.61 [1.14] mg/dL) and control (mean = 9.56 
[0.47] mg/dL)
Phosphate (after 3 months of paricalcitol):
Significantly higher (p < 0.05) for treatment with 
paricalcitol 1μg/day (mean = 3.34 [0.62] mg/dL) 
vs. control (mean = 3.20 [0.62] mg/dL)
Phosphate (after 6 months of paricalcitol):
No significant differences (p ≥ 0.05) between treat-
ment with paricalcitol 2μg/day (mean = 3.42 [0.71] 
mg/dL) and control (mean = 3.23 [0.62] mg/dL)
Creatinine clearance (mL/min./1.73 m2) after 
3 months of paricalcitol:
No significant differences (p ≥ 0.05) between 
treatment with paricalcitol 1μg/day (median = 
65.07 [47.79 -81.09]) and control (median = 
65.71 [50.90 -87.76])
Creatinine clearance (mL/min./1.73 m2) after 
6 months of paricalcitol:
Significantly lower (p < 0.01) for treatment with 
paricalcitol 2μg/day (median = 60.38 [44.10-
-79.24]) vs. control at the same time point 
(median = 68.11 [52.75 -87.04])
Proteinuria after 3 months of paricalcitol:
No significant differences (p ≥ 0.05) between 
treatment with paricalcitol 1μg/day (median = 
0.20 [0.13 -0.48] g/24h) and control (median = 
0.22 [0.14 -0.74] g/24h)
Proteinuria after 6 months of paricalcitol:
No significant differences (p ≥ 0.05) between 
treatment with paricalcitol 2μg/day (median = 
0.14 [0.10 -0.41] g/24h) and control (median = 
0.23 [0.10 -0.54] g/24h)
No serious adverse events were considered to 
be treatment -related
Hypercalcaemia was observed at one single 
occasion in two patients taking paricalcitol 2 
μg/day. Both events recovered with dose reduc-
tion to 1 μg/day. No hyperphosphatemia cases 
were reported
Calcium 365 days post -transplant:
Significantly (p < 0.001) higher for treatment 
(mean = 9.9 [0.5] mg/dL) vs. control (mean = 
9.7 [0.5] mg/dL)
Phosphorous: 365 days post -transplant:
No significant differences (p,=,0.11) between 
treatment (mean = 3.2 [0.6] mg/dL) and control 
(mean = 3.5 [0.6])
Estimated glomerular filtration rates (mL/
min./1.73 m2) 356 days post -transplant:
No significant (p = 0.66) differences between 
treatment (mean = 51.2 [15.4]) and control 
(mean = 52.7 [14.1])
Proteinuria 356 days post -transplant:
No significant (p = 0.21) differences between 
treatment (median = 91 [51 -177] mg/24h) and 
control [median = 118 (66 -242) mg/24h]
No serious adverse events were attributed to 
the study medication; only mild, reversible 
hypercalcaemia and hypercalciuria were attrib-
uted to paricalcitol (reversed by stopping cal-
cium supplement and, in some cases, discon-
tinuation of paricalcitol)
Calcium:
Significant (p < 0.01) increase from baseline 
(mean = 9.3 [0.5] mg/dL) to month 24 (9.6 [0.4] 
mg/dL)
Phosphorous:
Significant (p < 0.01) increase from baseline 
(mean= 3.4 [0.5] mg/dL) to month 24 (mean = 
3.5 [0.5] mg/dL)
Glomerular filtration rates (mL/min./1.73 m2):
No significant (p ≥ 0.05) differences between 
baseline (mean = 34.9 [14.1]) and month 24 
(33.9 [14.0])
Proteinuria:
Significant (p < 0.01) reduction from baseline 
(mean = 1.1 [0.7] g/24h) to month 24 (mean = 
0.7 [0.7] g/24h)
Mild hypercalcaemia and mild hyperphos-
phatemia (responded to paricalcitol dose reduc-
tion)
Calcium (treatment): Significant increase (p < 
0.001) from baseline (median = 9.34 [9.06 -9.57] 
mg/dL) to month 12 (median = 9.64 [9.28 -9.96] 
mg/dL)
Calcium (control): Non -significant changes (p 
= 0.027) from baseline (median = 9.60 [9.35-
-9.87] mg/dL) to month 12 (median = 9.85 
[9.55 -10.18] mg/dL)
Phosphorous (treatment):
Non -significant changes (p = 2.223) from base-
line (median = 3.10 [2.79 -3.44] mg/dL) to month 
12 (median = 3.13 [2.71 -3.47] mg/dL);
Phosphorous (control):
Non -significant changes (p = 1.764) from base-
line (median: 2.94 [2.52 -3.39] mg/dL) to month 
12 (median: 2.87 [2.50 -3.33] mg/dL)
Serum creatinine (treatment):
No significant change (p = 0.189) from baseline 
(median = 1.51 [1.22 -1.93] mg/dL) to month 12 
(1.47 [1.19 -1.80] mg/dL)
Serum creatinine (control):
No significant (p = 0.651) change from baseline 
(median = 1.40 [1.10 -1.70] mg/dL) to month 12 
(median 1.24 [1.12 -1.52] mg/dL)
Proteinuria (treatment):
No significant change (p = 1.884) from baseline 
(median = 0.18 [0.13–0.35] g/24h) to month 12 
(median = 0.21 [0.13–0.39] g/24h)
Proteinuria (control):
No significant change (p = 2.925) from baseline 
(median = 0.20 [0.13–0.41] g/24h) to month 12 
(median = 0.16 [0.12–0.50] g/24h)
Incidence of hypercalcemia and hyperphospha-
temia were not significantly different between 
treatment vs. control; serum levels of calcium 
increased in both groups, but remained within 
normal range
Not reported Not reported Only the treatment group had a significant (p = 
0.02) proteinuria reduction from baseline 
(mean = 481.6 [126.5]mg/L) to week 24 (mean 
= 203 [284] mg/L)
Episodes of hyperphosphatemia and hypercal-
caemia were not significantly different between 
the 2 groups
Calcium (after 3 months of treatment):
No significant (p = 0.719) changes from base-
line (mean = 9.63 [0.81] mg/dL) to month 3 
(mean = 9.57 [1.14] mg/dL)
Phosphate (after 3 months of treatment):
No significant changes (p = 0.957) from base-
line (mean = 3.41 [0.82] mg/dL) to month 3 
(mean = 3.40 [0.86] mg/dL)
Estimated glomerular filtration rates:
No significant (p = 0.784) changes from base-
line (mean = 35.5 [15.4]mL/min) to month 3 
(mean = 36.21 [15.5]mL/min)
No significant (p = 0.571) changes from base-
line (median = 436 [177 -772] mg/L) to month 3 
(median = 360 [177 -789] mg/L)
7 patients developed hypercalcaemia
ing a calcimimetic agent prior to transplant; cInclusion criteria: serum intact parathyroid hormone ≥150 pg/mL, serum calcium ≤10 mg/mL, and serum phosphorus ≤4.5mg/dL; dInclusion criteria: patients who were receiving a triple 
immunosuppressive regime consisting of prednisone, calcineurin inhibitor (cyclosporine or tacrolimus) and mycophenolate mofetil. eInclusion criteria: glomerular filtrate rate < 60 ml/min and secondary hyperparathyroidism; 
Exclusion criteria: glomerular filtration rate > 60 ml/min, intact parathyroid hormone levels < 110pg/ml, corrected Ca2+ > 10.5 mg, Phosphorus > 5.5 mg/dl; fTreated with paricalcitol 1 μg 3 times a week, for a minimum of 3 months.
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1 μg/day for 3 months which, if tolerated, was then 
increased to 2 μg/day45; 1 μg/day for 15 days which, 
if tolerated, was then increased to 2 μg/day48; 
1 μg on alternate days47; 1 μg/day46; 1 μg 3 times 
a week49. Only in one of the studies50 the dose of 
paricalcitol was not reported. To our knowledge, 
there are no randomised, double blind, controlled 
studies about the use of paricalcitol in kidney 
transplanted patients.
All studies demonstrated the efficacy of pari-
calcitol in reducing the plasmatic levels of PTH in 
kidney transplanted patients45 -50. The random-
ized, open -label, parallel two -arm study by Amer 
et al.48 was the largest study (100 patients) 
investigating the efficacy and safety of oral pari-
calcitol in the treatment of SHPT in kidney trans-
planted patients. The treatment group (51 patients) 
received 500 mg of elemental calcium twice a day, 
in combination with oral paricalcitol 1 μg/day 
(between days 3 and 15 post -transplant) which, 
in the absence of hypercalcaemia, was then 
increased to oral paricalcitol 2 μg/day from day 
15 post -transplant onwards, until the end of study 
(follow -up: 1 year). The control group (49 patients) 
was only treated with 500 mg of elemental cal-
cium twice a day. One year after kidney trans-
plantation, 15 patients (29%) in the treatment 
group had hyperparathyroidism when compared 
to 31 patients (63%) in the control group (p = 
0.0005). Furthermore, median plasmatic PTH con-
centrations identified in the treatment group (42 
pg/mL) were half of those identified in the control 
group (85 pg/mL).
All studies also demonstrated the safety of 
paricalcitol in kidney transplanted patients45 -50. 
For example, in the study by Amer et al.48 the 
levels of plasmatic calcium at the end of the study 
were significantly higher (p < 0.001) for the treat-
ment group (mean = 9.9 [0.5] mg/dL) versus the 
control (mean = 9.7 [0.5] mg/dL). Despite this, 
no patients developed severe hypercalcaemia 
(total plasmatic calcium > 11 mg/dL with symp-
toms). All hypercalcaemia events were reversible 
by stopping calcium supplement and, in some 
cases, discontinuation of paricalcitol. Further-
more, in the study by Prerez et al.46 the incidence 
of hypercalcaemia and hyperphosphatemia was 
not significantly different between oral paricalcitol 
and no treatment. Despite the increased plasmatic 
calcium levels in both groups, these remained 
within normal ranges. Similarly, in the study by 
Trillini et al.45 hypercalcaemia was only observed 
in 2 patients taking paricalcitol 2 μg/day, and this 
was resolved reducing this dose to 1 μg/day. 
Hyperphosphatemia was never observed. Finally, 
in the study by Oliden et al.50, episodes of hyper-
phosphatemia and hypercalcaemia were not sig-
nificantly different between patients taking oral 
paricalcitol and oral calcitriol.
Most studies also demonstrated that patients 
taking paricalcitol had a stable kidney function at 
the end of the study46 -50. Only in the study by Trillini 
et al.45, the creatinine clearance at the end of the 
study was significantly lower in patients taking pari-
calcitol (median 60.38 [44.10–79.24 mL/min./1.73 m2) 
than in those in the control group (median 68.11 
[52.75–87.04] mL/min./1.73 m2). However, this was 
probably a consequence of decreased creatinine 
tubular secretion, increased creatinine generation, 
or both, because paricalcitol is not nephrotoxic, as 
demonstrated by studies both in animals and in 
humans46 -51.
Furthermore, most studies did not identify signifi-
cant changes in proteinuria in patients taking pari-
calcitol45, 46, 48, 49. Indeed, as presented in Table I, 
this was only identified in the studies by Gonzalez 
et al.47 (mean proteinuria reduction in patients tak-
ing paricalcitol from 1.1 [0.7] g/24h to 0.7 [0.7] g/24h 
at month 24) and by Oliden et al.50 (patients taking 
paricalcitol had a significant [p = 0.02] mean pro-
teinuria reduction from 481.6 [126.5]mg/L to 203 
[284] mg/L).
In addition to the above, there is an ongoing 
study investigating whether the association between 
paricalcitol and dietary sodium restriction provides 
further proteinuria (albuminuria) reduction in non-
-diabetic CKD patients, on top of renin -angiotensin-
-aldosterone system (RAAS) blockade (ViRTUE study: 
vitamin D receptor activator and dietary sodium 
restriction to reduce residual urinary albumin excre-
tion in chronic kidney disease)52. This study is 
important because albuminuria reduction is a cor-
nerstone of CKD treatment, as albuminuria is a major 
contributor for CKD progression towards end -stage 
CKD53, and a predictor of CVD outcomes54. The first 
results of this study are expected starting from the 
3rd quarter of 2015.
Aníbal Ferreira, Inês Aires, Fernando Nolasco, Domingos Machado, Fernando Macário, 
Pedro L. Neves, António G. Costa, António M. N. Cabrita, Rui Castro, João B. Pereira
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  PILOT STUDIES INVESTIGATING 
THE TREATMENT OF VITAMIN D 
DEFICIENCY IN KIDNEY 
TRANSPLANTED PATIENTS
We undertook 2 prospective interventional pilot 
studies, investigating the efficacy and safety of the 
vitamin D deficiency treatment in kidney trans-
planted patients (see acknowledgements). In the first 
pilot study, kidney transplanted patients (naïve to 
vitamin D deficiency treatment, and on a stable dose 
of ACE inhibitors/ARAs) were treated with cholecal-
ciferol for 6 months, according to calcidiol levels 
(i.e., deficiency [< 15 ng/ml]; insufficiency [15 to 30 
ng/ml]; normal [> 30 ng/ml]).
The baseline characteristics of these patients are 
presented in Table II. Only 6.9% of the patients had 
normal calcidiol levels at baseline, whereas after 
treatment this number increased to 46.6% (see Table 
III). Mean serum PTH levels decreased significantly 
(p = 0.005) from 139.9 ± 95 to 114 ± 94 pg/ml, and 
mean proteinuria levels decreased significantly (p < 
0.0001) from 0.89 ± 1.2 g/day to 0.64 ± 0.9 g/day. 
Proteinuria was the highest in patients taking siro-
limus, and it was on these patients that it reduced 
the most (see Table IV). Finally, no significant (p > 
0.05) differences between baseline and study end 
were identified for plasmatic creatinine, 
haemoglobin, and phosphorous levels (see Table V). 
Therefore, our pilot study seemed to show that 6 
months treatment with cholecalciferol is an effective 
and safe treatment for vitamin D deficiency in kidney 
transplanted patients.
Our second pilot study included the first 36 
patients that concluded the pilot study described 
above. For the first 6 months, all patients (n = 36) 
were treated with cholecalciferol (mean dose: 2664 
IU) plus calcitriol (mean dose: 0.24 ± 0.02 μg). Then, 
for the following 6 months, 18 out of these patients 
remained on the same treatment, and 17 switched 
to therapy with cholecalciferol (mean dose: 2664 IU) 
plus paricalcitol (only one patients was lost to 
follow -up).
Table IV
Proteinuria levels according to immunosuppressive treatment, before 
and after 6 months treatment with cholecalciferol
Stratification 
according to calcidiol 
levels
Mean proteinuria 
levels at baseline 
(g/day)
Mean proteinuria 





Other regimen 0.7 0.35
 
Table III
Percentage of patients, per stratum of calcidiol levels, before and after 





After 6 months treatment 
with cholecalciferol 
(% patients)
Deficiency (< 15 ng/mL) 54.9 3.8
Insufficiency (15 to 30 ng/mL) 38.2 48.6
Normal (> 30 ng/mL) 6.9 46.6
 
Table II
Baseline characteristics of the patients





























Note: *19% of the patients developed NODAT
Table V
Creatinine, haemoglobin, calcium, and phosphorous levels, between 
baseline and after six months treatment with cholecalciferol
Baseline
After 6 months treatment 
with cholecalciferol
P -value*
Creatinine (mg/dL) 1.43 ± 0.6 1.46 ± 0.60 > 0.05
Haemoglobin (g/dL) 13.0 ± 1.5 12.9 ± 2.1 > 0.05
Calcium (mg/dL) 9.8 ± 1.2 9.8 ± 0.7 > 0.05
Phosphorous (mg/dL) 3.3 ± 0.8 3.4 ± 0.7 > 0.05
Note: *Wilcoxon test
Benefits of selective vitamin D receptor activators in kidney transplanted patients
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The results of this second pilot study seemed to 
show that 6 months treatment with cholecalciferol plus 
calcitriol did not significantly amplify the reduction of 
proteinuria, in kidney transplanted patients (see Table 
VI). However, replacing calcitriol by paricalcitol lead to 
a significant intensification of the reduction in protein-
uria, after 6 months of treatment (see Fig. 1).
Both pilot studies were only exploratory, as they 
included small sample sizes and no control groups. 
Despite this, these pilot studies provided valuable 
data to inform the larger and more robust studies 
that we are currently undertaking.
Three factors underline the clinical significance of 
undertaking such studies. Firstly, to our knowledge 
there are no published studies about the association 
of cholecalciferol plus paricalcitol. Secondly, this 
association successfully reduced proteinuria, in 
patients whose proteinuria did not reduce after 6 
months of treatment with cholecalciferol plus cal-
citriol. Finally, the doses of paricalcitol prescribed in 
association with cholecalciferol were lower, than those 
prescribed in single therapy. This may be a strategy 
for reducing the costs of paricalcitol therapy.
 CONCLUSION
Vitamin D deficiency has been associated with 
CVD, which is the leading cause of death in CKD. 
Table VI
Results of pilot study about treatment of kidney transplanted patients with cholecalciferol plus calcitriol, and cholecalciferol plus paricalcitol







Plasmatic calcium (mg/dl) 9.9 (0.8) 10.0 (0.9) 10.0 (0.9) NS
Plasmatic phosphorous (mg/dl) 3.3 (0.8) 3.5 (0.9) 3.6 (1.3) NS
Plasmatic PTH (pg/ml) 152.2 (99.0) 181.6 (105.6) 190.6 (± 142.3) NS
Proteinuria (g/24h) 1.5 (2.0) 1.3 (1.9) 0.9 (1.3) P < 0.05
Abbreviations: T -6, baseline (only calcitriol therapy); T0, after 6 months of cholecalciferol + calcitriol; T+6, after 6 months of switching calcitriol for paricalcitol; sd = standard 
deviation; * T0 vs. T+6 (Wilcoxon test)
Mean stable dose prescription during the 12 months (SD): Calcitriol 0.24 (0.02)μg; Cholecalciferol 2664 IU; Paricalcitol 0.94 (0.44) μg
Figure 1
Cholecalciferol supplementation plus paricalcitol after kidney transplantation.
Abbreviations: T -6, baseline (only calcitriol therapy); T0, after 6 months of cholecalciferol + calcitriol; T+6, after 6 
months of switching calcitriol for paricalcitol; * Wilcoxon test; ** Anova test
Mean stable dose prescription during the 12 months (SD): Calcitriol 0.24 (0.02) μg; Cholecalciferol 2664 IU; Parical-
citol 0.94 (0.44) μg
Aníbal Ferreira, Inês Aires, Fernando Nolasco, Domingos Machado, Fernando Macário, 
Pedro L. Neves, António G. Costa, António M. N. Cabrita, Rui Castro, João B. Pereira
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Therefore, to diagnose this deficiency, and to pre-
scribe an appropriate treatment, may potentially 
reduce morbidity and mortality in CKD patients. 
Vitamin D deficiency may be treated with native 
vitamin D, non -selective and selective VDRAs. How-
ever, selective VDRAs seem to be associated with 
improved survival rates, potentially due to non-
-inflammatory (including immunomodulatory) and 
anti -inflammatory effects, which were not described 
with other treatments.
Published studies suggest that paricalcitol is an 
effective and safe approach to reducing PTH levels 
in kidney transplanted patients. The use of calcimi-
metics in this population has not been approved, 
even though being frequently prescribed as an “off 
label” use. More research is still needed to investi-
gate the efficacy and safety of the combination of 
paricalcitol plus cholecalciferol in kidney trans-
planted patients, but our preliminary data suggests 
that it may be a cost -effective approach to reduce 
proteinuria levels. An ongoing study will provide 
important evidence on the role of the association 
between paricalcitol and sodium restriction, on top 
of RAAS blockade, on proteinuria reduction.
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